Citigroup’s BioTelemetry, Inc. BEAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-1,700
| Closed | -$123K | – | 7901 |
|
|
2020
Q4 | $123K | Sell |
1,700
-2,600
| -60% | -$136K | ﹤0.01% | 5377 |
|
|
2020
Q3 | $196K | Sell |
4,300
-14,000
| -77% | -$585K | ﹤0.01% | 4631 |
|
|
2020
Q2 | $827K | Buy |
18,300
+5,300
| +41% | +$237K | ﹤0.01% | 3762 |
|
|
2020
Q1 | $501K | Buy |
13,000
+8,800
| +210% | +$405K | ﹤0.01% | 3867 |
|
|
2019
Q4 | $194K | Sell |
4,200
-13,500
| -76% | -$585K | ﹤0.01% | 5216 |
|
|
2019
Q3 | $721K | Buy |
17,700
+1,300
| +8% | +$56.1K | ﹤0.01% | 3984 |
|
|
2019
Q2 | $790K | Buy |
16,400
+900
| +6% | +$47.3K | ﹤0.01% | 3931 |
|
|
2019
Q1 | $971K | Buy |
15,500
+2,100
| +16% | +$144K | ﹤0.01% | 3430 |
|
|
2018
Q4 | $800K | Buy |
13,400
+4,000
| +43% | +$240K | ﹤0.01% | 3631 |
|
|
2018
Q3 | $606K | Buy |
9,400
+2,800
| +42% | +$156K | ﹤0.01% | 4051 |
|
|
2018
Q2 | $297K | Sell |
6,600
-6,100
| -48% | -$243K | ﹤0.01% | 4640 |
|
|
2018
Q1 | $394K | Buy |
12,700
+6,800
| +115% | +$224K | ﹤0.01% | 4244 |
|
|
2017
Q4 | $176K | Sell |
5,900
-6,500
| -52% | -$188K | ﹤0.01% | 5168 |
|
|
2017
Q3 | $409K | Buy |
12,400
+4,700
| +61% | +$163K | ﹤0.01% | 4318 |
|
|
2017
Q2 | $258K | Sell |
7,700
-4,000
| -34% | -$119K | ﹤0.01% | 4582 |
|
|
2017
Q1 | $339K | Buy |
11,700
+7,700
| +193% | +$191K | ﹤0.01% | 4198 |
|
|
2016
Q4 | $89K | Buy |
+4,000
| New | +$78.2K | ﹤0.01% | 5844 |
|
Other funds holding BEAT
Citigroup's BEAT Position: Q1 2021 in Review
Citigroup sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 15,754 shares — an estimated $1.14M sold.
Citigroup first reported a position in BEAT in Q2 2013 and held it in 28 quarters. The position peaked at $4.27M in Q3 2018. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.
- Citigroup reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
- Citigroup sold 15,754 BioTelemetry, Inc. shares in Q1 2021, an estimated $1.14M.
- Citigroup first reported a position in BioTelemetry, Inc. in Q2 2013 and held it in 28 quarters.
- Citigroup's BioTelemetry, Inc. position peaked at $4.27M in Q3 2018.
- 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.
Based on Citigroup's 13F filing for Q1 2021, filed 13 May 2021.